LIM E, AMMONS S, MOHLER V, KILLIAN D, MALLADI A, GIKONYO K, LIN J; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. F-346.
XOMA (US) LLC, Berkeley, CA
BACKGROUND: Bactericidal/permeability-increasing protein (BPI) and compounds derived from it have anti-infective and anti-angiogenic properties. We have used directed synthesis to design a low molecular weight peptidomimetic (XMP.629) derived from functional domain II of human BPI and have investigated its anti-infective properties in vitro and in vivo. METHODS: In vitro antibacterial activity was determined using the NCCLS broth dilution protocol followed by plating on nutrient agar to confirm microbicidal action. Antifungal testing was performed in Sabourauds dextrose broth. Endotoxin-neutralizing activity was assessed using the RAW 264.7 cell differentiation assay. In vivo studies were performed on CD-1 mice in acute peritonitis and acute endotoxemia models. Mice were challenged IP with 1.4x10[7] CFU/mL E. coli O7:K1 and treated IP with XMP.629 or saline. In the endotoxemia model, mice were challenged IV with 25 mg/kg E. coli O111:B4 lipopolysaccharide and treated IV with XMP.629 or saline. In both models, mortality was recorded for seven days. RESULTS: XMP.629 exhibited microbicidal activity on clinically relevant organisms including Staphylococcus aureus, Pseudomonas aeruginosa,and Candida albicans. In acute peritonitis, XMP.629 treatment resulted in a dose dependent, significant increase in survival when compared to saline: 1 mg/kg (6 survivors/15 total, P<0.05), 3 mg/kg (11/15, P<0.001), 10 mg/kg (12/15, P<0.001) and saline (1/15). In acute endotoxemia, XMP.629 treatment resulted in a significant increase in survival when compared to saline: 1 mg/kg (14/15, P<0.01), 3 mg/kg (15/15, P<0.005), 10 mg/kg (14/15, P<0.01) and saline (5/15). CONCLUSION: XMP.629 demonstrated broad spectrum microbicidal and endotoxin-neutralizing activity, and represents a novel anti-infective agent.
Publication Types:
Keywords:
- Animals
- Anti-Bacterial Agents
- Anti-Infective Agents
- Blood Proteins
- Endotoxemia
- Endotoxins
- Humans
- In Vitro
- Lipopolysaccharides
- Membrane Proteins
- Mice
- Peptides
- Peritonitis
- Pseudomonas aeruginosa
- Ribonucleotides
- bactericidal permeability increasing protein
- immunology
- xanthosine monophosphate
Other ID:
UI: 102269891
From Meeting Abstracts